Companies / UroGen Pharma Ltd.

UroGen Pharma Ltd.

Nasdaq: URGNForeign · IFRSCIK 1668243RA'ANANA

Financials · FY2025

Revenue$109.79M
Net income$-153.49M
Total debt$200.00M
Cash$79.13M
Diluted EPS—
Shares outstanding48.9M

Ownership

48.9M shares outstanding · as of Jul 28, 2026
4.7%10%+ / strategic
Ownership
10%+ / strategic4.71%2,302,334
Public float95.29%46,578,230

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 7

View all →
Insider% of sharesShares
Arie Belldegrun, M.D.Director
——
Barrett Elizabeth A.CEOChief Executive Officer
——
Butitta Cynthia MDirector
——
Degnan ChrisChief Financial Officer
——
Robinson James A. Jr.Director
——
Schoenberg MarkChief Medical Officer
——
Smith Jason DrewGeneral Counsel
——

Institutional holders 0

HolderValue% of shares
No institutional holders on file.

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 3, 2026Schoenberg Mark
Executive
SellOrdinary Shares$72.6K-4K
-2.48%
144,985
0.30% of shares
low
Feb 3, 2026Smith Jason Drew
Executive
SellOrdinary Shares$63.3K-3K
-5.47%
55,588
0.11% of shares
low
Feb 3, 2026Smith Jason Drew
Executive
SellOrdinary Shares$52.3K-3K
-4.77%
52,934
0.11% of shares
low
Feb 3, 2026Schoenberg Mark
Executive
SellOrdinary Shares$36.3K-2K
-1.21%
150,514
0.31% of shares
low
Feb 3, 2026Schoenberg Mark
Executive
SellOrdinary Shares$36.3K-2K
-1.22%
148,671
0.30% of shares
low
Feb 3, 2026Smith Jason Drew
Executive
SellOrdinary Shares$31.7K-2K
-3.04%
51,326
0.11% of shares
low
Jun 22, 2026Arie Belldegrun, M.D.
Director
GrantStock Option (right ot buy)—+20K
20,000
0.04% of shares
low
Jun 22, 2026Butitta Cynthia M
Director
GrantRestricted Stock Unit—+8K
8,000
0.02% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Toronto Dominion BankPassive13G/A—2,302,334—